These findings are consistent with the established biology of thyroid tumors: BRAF mutations are strongly associated with classic PTC, while FV-PTC is more frequently driven by RAS mutations, and medullary carcinoma by RET alterations [37,38,39]. The gene discussed is BRAF; the disease is medullary thyroid gland carcinoma.